Total trials
1,389
Active
274
Phase 3
58
Total enrollment
569,523
Pipeline matrix
Showing 40 of 175 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | 18 | |||||
| Gardasil-9 | — | — | — | — | — | 2 | |
| Infliximab | — | — | — | — | 5 | ||
| Supplemental insulin | — | — | — | — | — | 4 | |
| Methylprednisolone | — | — | — | — | 3 | ||
| Lidocaine | — | — | — | — | 3 | ||
| Levodopa | — | — | — | — | 2 | ||
| Quadrivalent seasonal influenza vaccine | — | — | — | — | — | 2 | |
| Famotidine | — | — | — | — | 2 | ||
| Montelukast | — | — | — | — | 2 | ||
| Carbidopa Levodopa | — | — | — | — | — | 2 | |
| Botulinum toxin | — | — | — | — | — | 1 | |
| Oral Anti-diabetes Drugs alone | — | — | — | — | — | 1 | |
| Basal bolus insulin | — | — | — | — | — | 1 | |
| Insulin | — | — | — | — | — | 1 | |
| Atropine challenge | — | — | — | — | — | 1 | |
| Influenza Vaccine | — | — | — | — | — | 1 | |
| Low Dose Naltrexone | — | — | — | — | — | 1 | |
| Moderna RSV vaccine | — | — | — | — | — | 1 | |
| 10 mg IV dexamethasone & 6 day oral methylprednisolone taper | — | — | — | — | — | 1 | |
| Trumenba | — | — | — | — | — | 1 | |
| PENBRAYA | — | — | — | — | — | 1 | |
| Acetaminophen | — | — | — | — | — | 1 | |
| Loratadine | — | — | — | — | — | 1 | |
| Motixafortide | — | — | — | — | — | 1 | |
| Recombinant Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| Live Attenuated Yellow Fever 17D Vaccine | — | — | — | — | — | 1 | |
| Prophylactic Transfusion Intervention group: Transfusion | — | — | — | — | — | 1 | |
| Lidocaine injections | — | — | — | — | — | 1 | |
| Triamcinolone injection to the shoulder, elbow, wrist, or hand | — | — | — | — | — | 1 | |
| Ketorolac injection to the shoulder, elbow, wrist, or hand | — | — | — | — | — | 1 | |
| Doxycycline monohydrate 200 mg | — | — | — | — | — | 1 | |
| Glycerin Suppository | — | — | — | 3 | |||
| Lorazepam | — | — | — | — | 2 | ||
| Oxycodone 5 mg | — | — | — | — | — | 2 | |
| Leuprolide | — | — | — | — | 2 | ||
| Relugolix | — | — | — | — | 2 | ||
| Emicizumab | — | — | — | — | 2 | ||
| Prednisone | — | — | 5 |
135 more active programs hidden
Next readouts
- 2022-02-02
- 2022-05-02
- 2022-06-06
- 2022-09-27
- 2023-05-17
- 2023-12-15
- 2024-01-15
- 2024-03-15
- 2024-09-13
- 2024-10-23
Top conditions
- HIV33
- Diabetes32
- Depression28
- Sickle Cell Disease26
- Coronary Artery Disease25
- Breast Cancer24
- Obesity19
- Stroke17
Frequently asked questions about Emory University
- How many clinical trials does Emory University have on ClinicalTrials.gov?
- Emory University is listed as the lead sponsor on 1,389 clinical trials in ClinicalTrials.gov, 274 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Emory University's trials are in Phase 3?
- 58 of Emory University's trials are in Phase 3, spread across 175 active drug programs.
- What therapeutic areas does Emory University focus on?
- Emory University's most-studied conditions on ClinicalTrials.gov are HIV, Diabetes, Depression, Sickle Cell Disease, Coronary Artery Disease.
- When are Emory University's next clinical trial readouts?
- Emory University has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer”, expected around 2022-02-02.